A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

~9 mi. (Hobart, Australia, +89 more cities)

ICON Cancer Care Hobart

ER Positive, +1 more biomarker

Breast Carcinoma

giredestrant, +1 more drug

hormone therapy

Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer

~9 mi. (Hobart, Australia, +151 more cities)

GSK Investigational Site

Non-Small Cell Lung Carcinoma

niraparib, +1 more drug

immunotherapy, +1 more type

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

~9 mi. (Hobart, Australia, +141 more cities)

GSK Investigational Site

Multiple Myeloma

belantamab mafodotin

chemotherapy, +1 more type

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

~9 mi. (Hobart, Australia, +46 more cities)

Royal Hobart Hospital

Prostate Adenocarcinoma

darolutamide, +2 more drugs

hormone therapy, +1 more type

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

~9 mi. (Hobart, Australia, +96 more cities)

Royal Hobart Hospital

Diffuse Large B-Cell Lymphoma, +1 more condition

brentuximab vedotin, +2 more drugs

chemotherapy, +1 more type

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

~9 mi. (Hobart, Australia, +142 more cities)

Royal Hobart Hospital

del(11)(q10), +27 more biomarkers

Myelofibrosis

imetelstat, +1 more drug

targeted therapy

A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

~9 mi. (Hobart, Australia, +50 more cities)

Royal Hobart Hospital

B-Cell Non-Hodgkin Lymphoma, +1 more condition

atezolizumab, +1 more drug

immunotherapy

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

~9 mi. (Hobart, Australia, +118 more cities)

Regeneron Research Facility

Skin Squamous Cell Carcinoma

cemiplimab

immunotherapy

DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

~9 mi. (Hobart, Australia, +43 more cities)

Royal Hobart Hospital

Malignant Pleural Mesothelioma

chemotherapy, +1 more drug

chemotherapy, +1 more type

Tislelizumab Plus BGB-A1217 Versus Tislelizumab Versus Durvalumab When Co-administered With Concurrent Chemoradiotherapy (cCRT) in Lung Cancer

~9 mi. (Hobart, Australia, +7 more cities)

Royal Hobart Hospital

Non-Small Cell Lung Carcinoma

chemotherapy, +3 more drugs

chemotherapy, +1 more type

TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

~9 mi. (Hobart, Australia, +144 more cities)

Royal Hobart Hospital

EGFR Exon 20 Insertion

Non-Squamous Non-Small Cell Lung Carcinoma

mobocertinib

targeted therapy

RegoNivo vs Standard of Care Chemotherapy in AGOC

~9 mi. (Hobart, Australia, +51 more cities)

Royal Hobart Hospital

Adenocarcinoma of the Gastroesophageal Junction, +2 more conditions

nivolumab, +1 more drug

immunotherapy, +1 more type